Skip to Main content Skip to Navigation
New interface
Journal articles

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.

Abstract : Insulin degludec (IDeg) is a novel antiglycemic agent belonging to the therapeutic class of ultra-long duration basal insulin analogs. Its half-life and duration of action are 25 hours and 42 hours, respectively. This pharmacodynamic profile leads to a strict dosing schedule, ie, IDeg is injected at the same time each day to ensure optimal biological action and consistent glycemic control. According to the literature, IDeg provides glycemic control and nocturnal hypoglycemia reduction comparable with other long-acting analogs in type 2 diabetes mellitus. The risk of severe hypoglycemic episodes seems also to be reduced when using IDeg therapy; however, long-term follow-up is warranted for monitoring of possible but relatively infrequent adverse events. IDeg is also available in combination with aspart insulin and with liraglutide. The above preparations have been approved by the European Medicines Agency and other national health authorities. In 2012, the US Food and Drug Administration asked for a complementary study on IDeg-associated cardiovascular risk. Future prospective evaluation of large cohorts of patients with type 2 diabetes mellitus treated with IDeg, with long-term follow-up, can provide further relevant information on the safety of IDeg therapy.
Document type :
Journal articles
Complete list of metadata
Contributor : Ghislaine Calvez Connect in order to contact the contributor
Submitted on : Friday, February 19, 2016 - 11:00:27 AM
Last modification on : Tuesday, April 19, 2022 - 10:13:18 AM

Links full text




Philippe Thuillier, Zarrin Alavi, Véronique Kerlan. Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes.. Diabetes, metabolic syndrome and obesity : targets and therapy, 2014, 8, pp.483-93. ⟨10.2147/DMSO.S54953⟩. ⟨hal-01276312⟩



Record views